Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia

Clin Transl Oncol. 2021 Sep;23(9):1963-1966. doi: 10.1007/s12094-021-02590-0. Epub 2021 Mar 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Disease-Free Survival
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Recurrence
  • Treatment Outcome

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents
  • blinatumomab